Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.

MLA

Trifilio, Steven, et al. “Idarubicin Appears Equivalent to Dose-Intense Daunorubicin for Remission Induction in Patients with Acute Myeloid Leukemia.” Leukemia Research, vol. 37, no. 8, Aug. 2013, pp. 868–71. EBSCOhost, https://doi.org/10.1016/j.leukres.2013.04.009.

APA

Trifilio, S., Zhou, Z., Mehta, J., Czerniak, C., Pi, J., Greenberg, D., Koslosky, M., Pantiru, M., & Altman, J. (2013). Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia. Leukemia Research, 37(8), 868–871. https://doi.org/10.1016/j.leukres.2013.04.009

Chicago

Trifilio, Steven, Zheng Zhou, Jayesh Mehta, Colleen Czerniak, Judy Pi, Deborah Greenberg, Molly Koslosky, Mihaela Pantiru, and Jessica Altman. 2013. “Idarubicin Appears Equivalent to Dose-Intense Daunorubicin for Remission Induction in Patients with Acute Myeloid Leukemia.” Leukemia Research 37 (8): 868–71. doi:10.1016/j.leukres.2013.04.009.